15 completed, 1 withdrawn. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 15, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow Dengue Fever: new trials by email Literature Review of Dengue Fever trials Research Report on Dengue Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Celgosivir, Modipafant 50mg, Placebo - Dengue Fever | Phase 1 / Phase 2 | Withdrawn | Singapore General Hospital | 2018-12-01 | 2020-03-23 | |
| Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity TDV - Dengue Fever | Phase 1 | Completed | Takeda | 80 | 2013-01-22 | 2019-07-18 |
| A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant, Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant, Phosphate buffered saline - Dengue Fever | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 100 | 2012-11-01 | 2017-05-23 |
| A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline - Dengue Fever | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 100 | 2012-09-01 | 2019-01-25 |
| Celgosivir as a Treatment Against Dengue celgosivir, placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Singapore General Hospital | 50 | 2012-07-01 | 2013-12-02 |
| Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg - Dengue Fever | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 20 | 2011-12-01 | 2015-04-22 |
| Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease Tetravalent Dengue Vaccine (TVDV), Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose), Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose) - Dengue Disease, Dengue Fever | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 40 | 2011-12-01 | 2016-11-04 |
| Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever TDV - Low Dose, TDV - High Dose, Placebo - Dengue Fever | Phase 1 | Completed | Inviragen Inc. | 96 | 2010-10-11 | 2018-06-19 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults rDEN3delta30/31-7164 - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2009-09-01 | 2013-11-15 |
| Study of HBV-001 D1 in Healthy Adults DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E - Dengue Fever | Phase 1 | Completed | Hawaii Biotech, Inc. | 16 | 2009-07-01 | 2011-02-07 |
| Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine rDEN2/4delta30(ME) vaccine, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2009-01-01 | 2013-01-03 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults rDEN4delta30-200,201, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2006-06-01 | 2013-01-03 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults rDEN2/4delta30(ME) Vaccine, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 28 | 2005-01-01 | 2008-01-21 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults rDEN1delta30, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 28 | 2004-09-01 | 2008-01-18 |
| A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Dengue Vaccine Formulation 17, Licensed Japanese Encephalitis (JE) Vaccine - Dengue Fever | Phase 1 / Phase 2 | Completed | U.S. Army Medical Research and Development Command | 7 | 2003-08-01 | 2014-02-24 |
Dengue (16) · Severe Dengue (7)
Arbovirus Infections (16) · Flaviviridae Infections (16) · Flavivirus Infections (16) · Hemorrhagic Fevers, Viral (16) · Infections (16) · Mosquito-Borne Diseases (16) · RNA Virus Infections (16) · Vector Borne Diseases (16) · Virus Diseases (16)
Vaccines (4) · Aluminum Hydroxide (3) · celgosivir (2) · Biological Products (1) · Dengue Vaccines (1) · modipafant (1) · vaxfectin (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · U.S. Army Medical Research and Development Command (5) · Singapore General Hospital (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Hawaii Biotech, Inc. (1) · Inviragen Inc. (1) · Takeda (1)
United States (10) · Singapore (2) · Bangladesh (1) · Colombia (1) · Puerto Rico (1) · Thailand (1)
Anna Durbin, MD (5) · Beth-Ann Coller, PhD (1) · Clemente Diaz, MD (1) · Ivan D Velez, MD, Ph.D. (1) · Janine R Danko, MD (1) · Jenny Low, Dr (1) · Leyi Lin, MD (1) · Sriluck Simasathien, MD (1) · Stephen Thomas, MD (1) · Subhash Vasudevan, PhD (1)
PMID 26383952, PMID 18337339, PMID 24877997, PMID 25087476, PMID 26458804, PMID 26794905, PMID 27509020, PMID 28719287, PMID 29512481, PMID 30010906, PMID 32394880